HDAC9 and female reproductive organ cancer: In conclusion, epidrugs such as azacitidine, decitabine, and HDAC inhibitors significantly enhance ICI therapy in gynecological cancers by reprogramming the immunosuppressive TME, upregulating immune-related genes, and promoting effector T and NK cell infiltration and activity.